A detailed history of Deutsche Bank Ag\ transactions in Aquestive Therapeutics, Inc. stock. As of the latest transaction made, Deutsche Bank Ag\ holds 37,819 shares of AQST stock, worth $173,589. This represents 0.0% of its overall portfolio holdings.

Number of Shares
37,819
Holding current value
$173,589
% of portfolio
0.0%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

BUY
$2.4 - $5.09 $90,765 - $192,498
37,819 New
37,819 $188,000
Q4 2021

Feb 11, 2022

SELL
$3.69 - $6.37 $77 - $133
-21 Closed
0 $0
Q3 2021

Nov 04, 2021

SELL
$3.25 - $4.66 $4,475 - $6,416
-1,377 Reduced 98.5%
21 $0
Q2 2021

Aug 11, 2021

SELL
$3.29 - $5.21 $41,894 - $66,344
-12,734 Reduced 90.11%
1,398 $6,000
Q1 2021

May 13, 2021

SELL
$4.17 - $6.73 $19,953 - $32,203
-4,785 Reduced 25.29%
14,132 $73,000
Q4 2020

Feb 16, 2021

SELL
$4.65 - $7.79 $424,824 - $711,694
-91,360 Reduced 82.85%
18,917 $101,000
Q3 2020

Nov 12, 2020

BUY
$4.12 - $9.09 $411,620 - $908,163
99,908 Added 963.53%
110,277 $535,000
Q2 2020

Aug 13, 2020

BUY
$1.84 - $6.44 $19,078 - $66,776
10,369 New
10,369 $50,000
Q3 2019

Nov 14, 2019

SELL
$3.04 - $4.91 $12,029 - $19,428
-3,957 Closed
0 $0
Q2 2019

Aug 14, 2019

SELL
$3.72 - $6.95 $31,374 - $58,616
-8,434 Reduced 68.07%
3,957 $15,000
Q1 2019

May 15, 2019

BUY
$5.74 - $8.05 $45,426 - $63,707
7,914 Added 176.77%
12,391 $84,000
Q4 2018

Feb 14, 2019

SELL
$6.09 - $18.0 $44,913 - $132,750
-7,375 Reduced 62.23%
4,477 $27,000
Q3 2018

Dec 21, 2021

BUY
$15.0 - $18.96 $20,670 - $26,126
1,378 Added 13.16%
11,852 $207,000
Q3 2018

Nov 14, 2018

BUY
$15.0 - $18.96 $157,110 - $198,587
10,474 New
10,474 $182,000

Others Institutions Holding AQST

About Aquestive Therapeutics, Inc.


  • Ticker AQST
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 53,350,700
  • Market Cap $245M
  • Description
  • Aquestive Therapeutics, Inc., a pharmaceutical company, focuses on identifying, developing, and commercializing various products to address unmet medical needs in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual f...
More about AQST
Track This Portfolio

Track Deutsche Bank Ag\ Portfolio

Follow Deutsche Bank Ag\ and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Deutsche Bank Ag\, based on Form 13F filings with the SEC.

News

Stay updated on Deutsche Bank Ag\ with notifications on news.